secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-037588
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Q4 net loss $70.8M, cash $851M; KT-621 Phase 1 data June 2025
--------------------------------------------------------------------

- Net loss Q4 2024 $70.8M, full year $223.9M; collaboration revenue Q4 $7.4M vs $47.9M YoY.
- Cash $851M as of Dec 31, 2024; runway into mid-2027.
- KT-621 Phase 1 SAD/MAD data June 2025; Phase 1b AD starts 2Q25 with data 4Q25; Phase 2b AD/asthma 4Q25/1Q26.
- KT-295 (TYK2) Phase 1 starts 2Q25 with data 4Q25; new first-in-class program announced May 2025.
- Director Leigh Morgan not standing for reelection; no disagreement with company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/0001193125-25-037588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/d922874d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-037588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer